CORDIS · 101000607 · H2020
OXIPRO Transition towards environment-friendly consumer products by co-creation of an oxidoreductase foundry
Coordinator: NORCE RESEARCH AS (NO)
OXIPRO will contribute to the transition towards greener detergents, textiles, cosmetics and nutraceuticals by co-creating and co-developing an efficient oxidoreductase foundry under an interdisciplinary and systemic innovation approach, integrating high-performance computing and cutting-edge biotechnology. Oxidoreductases offer promising, yet underexploited solutions for enhancing sustainability in consumer products. Oxidoreductases are able to replace strong toxic and harmful oxidizers, create novel functionalities in substrates, transform waste to valuable products, and improve quality, ap…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
EU contribution: €6.0M awarded to the consortium. The project runs over approximately 4 years from 2021-06-01 to 2025-05-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from NO
see all →- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · H2020 · €100.0M
- CHIKVAX_CHIM — Late-stage clinical development of Chikungunya vaccines in endemic countries (CHIKV) and Controlled Human Infection Models for SARS-CoV2 and other beta coronaviruses (CHIM).101126531 · HORIZON · €70.0M
- ECRC — Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola857934 · H2020 · €36.0M
- FILOVAX — Development of Broadly Protective Filovirus Vaccines101167138 · HORIZON · €35.0M
- RIFTVAX — Clinical development of Rift Valley fever vaccines in endemic regions101081290 · HORIZON · €35.0M
- REFHYNE II — Clean Refinery Hydrogen for Europe II101036970 · H2020 · €32.4M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
- HBP SGA1 — Human Brain Project Specific Grant Agreement 1720270 · CH · €89.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €6.0M toward a total project budget of €6.0M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-FNR-2020.
- Who coordinates the project?
- The project is coordinated by NORCE RESEARCH AS (NO).
- What is the project timeline?
- The project runs from 2021-06-01 to 2025-05-31 — approximately 4 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 101000607.